Acadia chief warns Trump 'most favoured nation' policy threatens global drug R&D partnerships

 The chief executive of Acadia Pharmaceuticals has warned that President Donald Trump's "most favoured nation" pricing policy risks undermining the international research collaborations that have underpinned drug discovery for decades, in the latest sign of mounting industry concern over the regulatory and commercial direction of US pharmaceutical policy.

Catherine Owen Adams, who took over as chief executive of the San Diego-based central nervous system specialist last September, used a pharmaceutical industry summit on 14 May to argue that the proposed pricing framework could hinder the international R&D partnerships that have long supported the discovery and development of novel medicines. Her intervention echoes the warning issued earlier this year by Emer Cooke, the head of the European Medicines Agency, who told a Reuters conference in Barcelona that the industry was at "a very critical point" as the consequences of Trump's pricing reset rippled through clinical trial siting, launch strategies and global investment patterns.

Owen Adams's concern is significant because of Acadia's positioning in the industry. The Nasdaq-listed biotech carries a market capitalisation of roughly $3.79bn and has built its commercial franchise on two products: NUPLAZID, for Parkinson's disease psychosis, and DAYBUE, for Rett syndrome. Together, the two drugs are projected to generate annual revenues of between $1.5bn and $2bn at peak. Her warning sits alongside a broader industry argument: that "most favoured nation" pricing, which seeks to link US drug prices to those paid in other wealthy countries, will discourage drugmakers from launching new products in lower-priced jurisdictions for fear of dragging down US pricing — and more broadly, will compress the international cash flows that fund early-stage research.

Industry leaders at the summit also flagged the competitive intensification taking place in Chinese biopharmaceutical research and development. China has emerged as a meaningful rival in drug discovery and clinical development, propelled by lower trial costs, faster patient recruitment and an increasingly sophisticated scientific base. The discussion at the summit highlighted the need for the United States to maintain robust public funding for academic research institutions if it is to defend its position as the dominant global hub of biopharmaceutical innovation — a position that has historically rested as much on universities, the National Institutes of Health and the Food and Drug Administration as on private capital.

For Acadia specifically, the international dimension of pharmaceutical development is more than rhetorical. The group has been pursuing a deliberate transition from a US-focused commercial operator into what Owen Adams has described as a "global biotech powerhouse" in neurology, neuropsychiatry and rare diseases. Acadia's pipeline includes mid- and late-stage programmes in Alzheimer's disease psychosis and Lewy body dementia psychosis, alongside earlier-stage assets in other unmet patient populations. Together, five experimental medicines could, if they reach the market, collectively generate peak annual sales of approximately $12bn — though the company's leadership acknowledges that neuroscience drug development remains notoriously difficult and setback-prone.

The company is also positioning itself as a more "assertive" deal-maker, with Owen Adams signalling that external innovation — in-licensing, acquisitions and partnerships — will be central to advancing the pipeline. That strategic posture makes the broader regulatory and pricing environment particularly consequential. If "most favoured nation" pricing depresses returns on US-launched products and discourages partnerships across jurisdictions, mid-cap biotechs like Acadia — which lack the scale of large pharmaceutical groups but depend on the same cross-border research ecosystem — are likely to be among the most exposed.

The financial picture at Acadia is mixed. The stock trades at a price-to-earnings multiple of 10.07 times, well below biotechnology peers, suggesting some valuation support for current earnings. But the forward multiple of 56.95 times reflects the market's pricing of significant future growth, which in turn depends on successful pipeline execution. Insider activity has been net selling: company insiders disposed of roughly $0.8mn of shares over the past three months, with no purchases reported — a pattern that some analysts read as a cautious near-term signal, though insider sales typically also reflect equity compensation cycles rather than directional conviction. Acadia's profitability ranking remains low relative to its growth ranking, indicating the company is still in the operational phase of converting its development investment into sustained earnings.

The broader strategic question Owen Adams has chosen to amplify is one that the pharmaceutical industry has been quietly worrying about for months. Trump's "most favoured nation" framework, formally announced in May 2025, has already begun to disrupt the calculus of drug launches in Europe and elsewhere, with several major manufacturers delaying or repricing products in lower-priced markets to protect US economics. The longer-term concern is that the policy could fundamentally reshape the geography of pharmaceutical research, manufacturing and commercialisation — pushing investment toward jurisdictions where pricing flexibility is greater, talent and capital are increasingly available, and the regulatory environment is more accommodating to industrial-scale clinical development.

For US pharmaceutical leadership, the structural question is whether a policy framework intended to deliver short-term political gains on drug prices can avoid eroding the longer-term scientific and economic returns that have underpinned the industry's global pre-eminence. The fact that mid-cap biotech chief executives like Owen Adams are now publicly questioning the impact of the policy — at a moment of significant operational ambition for their own companies — suggests that industry confidence in the trajectory of US pharmaceutical policy is materially weakening.

Whether the warnings translate into a policy recalibration remains to be seen. The Trump administration has shown limited appetite for compromise on drug pricing, and the political logic of the most favoured nation framework retains significant domestic appeal. For now, the more probable outcome is that pharmaceutical executives — from the largest multinationals to the mid-cap specialists like Acadia — will continue to recalibrate their investment, launch and partnership strategies around a regulatory environment that has become substantially less predictable than at any point in the past decade.